Correlation of γ-catenin expression with good prognosis in medulloblastomas

Journal of Neurosurgery

Volumn 102 PEDIATRICS, Issue SUPPL. 2, 2005, Pages 197-206

  Misaki, Koichi ^b   Marukawa, Kohei ^b   Hayashi, Yutaka ^b   Fukusato, Toshio ^b   Minamoto, Toshinari ^b   Hasegawa, Mitsuhiro ^b   Yamashita, Junkoh ^b   Fujisawa, Hironori ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NONE

Author keywords

catenin; C myc; Cyclin D1; Medulloblastoma; N myc; Prognostic factor

Indexed keywords

BETA CATENIN; BETA INTERFERON; CARBOPLATIN; CISPLATIN; CYCLIN D1; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; NIMUSTINE; PLAKOGLOBIN; VINCRISTINE; WNT PROTEIN; CANCER ANTIBODY; CTNNB1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; DESMOPLAKIN; JUP PROTEIN, HUMAN; MESSENGER RNA; PRIMER DNA; TRANSACTIVATOR PROTEIN;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHROMOSOME ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MEDULLOBLASTOMA; ONCOGENE C MYB; ONCOGENE C MYC; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; WESTERN BLOTTING; CEREBELLUM TUMOR; GENETICS; IMMUNOLOGY; INFANT; MULTIMODALITY CANCER THERAPY; NUCLEOTIDE SEQUENCE; ONCOGENE MYC; POINT MUTATION; PRESCHOOL CHILD; PROTO ONCOGENE;

ADOLESCENT; ADULT; ANTIBODIES, NEOPLASM; BETA CATENIN; BLOTTING, WESTERN; CEREBELLAR NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYTOSKELETAL PROTEINS; DESMOPLAKINS; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; GAMMA CATENIN; GENES, BCL-1; GENES, MYC; HUMANS; IMMUNOHISTOCHEMISTRY; INFANT; MEDULLOBLASTOMA; POINT MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; RNA, MESSENGER; TRANS-ACTIVATORS;

EID: 26944482436     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2005.102.2.0197     Document Type: Article

References (61)

1. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS, et al: MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med 126:540-544, 2002
2. Amitay R, Nass D, Meitar D, Goldberg I, Davidson B, Traichtenbrot L, et al: Reduced expression of plakoglobin correlates with adverse outcome in patients with neuroblastoma. Am J Pathol 159:43-49, 2001
3. Badiali M, Pession A, Basso G, Adreini L, Rigobello L, Galassi E, et al: N-myc and c-myc oncogenes amplification in medulloblastomas. Evidence of particularly aggressive behavior of a tumor with c-myc amplification. Tumori 77:118-121, 1991
4. Baeza N, Masuoka J, Kleihues P, Ohgaki H: AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene 22:632-636, 2003
5. Barker N, Clevers H: Catenins, Wnt signaling and cancer. Bioessays 22:961-965, 2000
6. Brown HG, Kepner JL, Perlman EJ, Friedman HS, Strother DR, Duffner PK, et al: "Large cell/anaplastic" medulloblastomas: a Pediatric Oncology Group Study. J Neuropathol Exp Neurol 59:857-865, 2000
7. Caca K, Kolligs FT, Ji X, Hayes M, Qian J, Yahanda A, et al: β-and γ-catenin mutations, but not E-cadherin inactivation, underlie T-cell factor/lymphoid enhancer factor transcriptional deregulation in gastric and pancreatic cancer. Cell Growth Differ 10:369-376, 1999
8. Carlos de Vicente J, Herrero-Zapatero A, Fresno MF, Lopez-Arranz JS: Expression of cyclin D1 and Ki-67 in squamous cell carcinoma of the oral cavity: clinicopathological and prognostic significance. Oral Oncol 38:301-308, 2002
9. Chang CH, Housepian EM, Herbert C Jr: An operative staging system and a megavoltage radiotherapeutic technique for cerebellar medulloblastomas. Radiology 93:1351-1359, 1969
10. David KM, Casey AT, Hayward RD, Harkness WF, Phipps K, Wade AM: Medulloblastoma: is the 5-year survival rate improving? A review of 80 cases from a single institution. J Neurosurg 86:13-21, 1997
11. Eberhart CG, Burger PC: Anaplasia and grading in medulloblastomas. Brain Pathol 13:376-385, 2003
12. Eberhart CG, Kratz JE, Schuster A, Goldthwaite P, Cohen KJ, Perlman EJ, et al: Comparative genomic hybridization detects an increased number of chromosomal alterations in large cell/anaplastic medulloblastomas. Brain Pathol 12:36-44, 2002
13. Eberhart CG, Tihan T, Burger PC: Nuclear localization and mutation of beta-catenin in medulloblastomas. J Neuropathol Exp Neurol 59:333-337, 2000
14. Ellison D: Classifying the medulloblastoma: insights from morphology and molecular genetics. Neuropathol Appl Neurobiol 28:257-282, 2002
15. Ellison DW, Clifford SC, Gajjar A, Gilbertson RJ: What's new in neuro-oncology? Recent advances in medulloblastoma. Eur J Paediatr Neurol 7:53-66, 2003
16. Fujisawa H, Kurrer M, Reis RM, Yonekawa Y, Kleihues P, Ohgaki H, et al: Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter. Am J Pathol 155:387-394, 1999
17. Fujisawa H, Marukawa K, Hasegawa M, Tohma Y, Hayashi Y, Uchiyama N, et al: Genetic differences between neurocytoma and dysembryoplastic neuroepithelial tumor and oligodendroglial tumors. J Neurosurg 97:1350-1355, 2002
18. Fujisawa H, Takabatake Y, Fukusato T, Tachibana O, Tsuchiya Y, Yamashita J: Molecular analysis of the rhabdoid predisposition syndrome in a child: a novel germline hSNF5/INI1 mutation and absence of c-myc amplification. J Neurooncol 63:257-262, 2003
19. Giangaspero F, Bigner SH, Kleihues P, et al: Medulloblastoma, in Kleihues P, Cavenee WK (eds): Pathology and Genetics. Tumors of the Nervous System. Lyon, France: IARC Press, 2000, pp 129-137
20. Giangaspero F, Perilongo G, Fondelli MP, Brisigotti M, Carollo C, Burnelli R, et al: Medulloblastoma with extensive nodularity: a variant with favorable prognosis. J Neurosurg 91:971-977, 1999
21. Gilbert J, Norris MD, Haber M, Kavallaris M, Marshall GM, Stewart BW: Determination of N-myc gene amplification in neuroblastoma by differential polymerase chain reaction. Mol Cell Probes 7:227-234, 1993
22. Grotzer MA, Hogarty MD, Janss AJ, Liu X, Zhao H, Eggert A, et al: MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 7:2425-2433, 2001
23. Grotzer MA, Janss AJ, Fung KM, Biegel JA, Sutton LN, Rorke LB, et al: TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 18:1027-1035, 2000
24. Hamilton SR, Liu B, Parsons RE, Papadopoulos N, Jen J, Powell SM, et al: The molecular basis of Turcot's syndrome. N Engl J Med 332:839-847, 1995
25. Hayashi Y, Ueki K, Waha A, Wiestler OD, Louis DN, von Diemling A: Association of EGFR gene amplification and CDKN2 (p16/MTS1) gene deletion in glioblastoma multiforme. Brain Pathol 7:871-875, 1997
26. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, et al: Identification of c-MYC as a target of the APC pathway. Science 281:1509-1512, 1998
27. Herms J, Neidt I, Luscher B, Sommer A, Schürmann P, Schröeder T, et al: C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 89:395-402, 2000
28. Huang H, Mahler-Araujo BM, Sankila A, Chimelli L, Yonekawa Y, Kleihues P, et al: APC mutations in sporadic medulloblastomas. Am J Pathol 156:433-437, 2000
29. Iwato M, Tachibana O, Tohma Y, Nitta H, Hayashi Y, Yamashita J: Molecular analysis for p53 and mdm2 in intracranial germ cell tumors. Acta Neuropathol (Berl) 99:21-25, 2000
30. Jenkin D, Shabanah MA, Shail EA, Gray A, Hassounah M, Khafaga Y, et al: Prognostic factors for medulloblastoma. Int J Radiat Oncol Biol Phys 47:573-584, 2000
31. Kandel R, Zhu XL, Li SQ, Rohan T: Cyclin D1 protein overexpression and gene amplification in benign breast tissue and breast cancer risk. Eur J Cancer Prev 10:43-51, 2001
32. Kaneko T, Yamashima T, Tohma Y, Nomura M, Imajoh-Ohmi S, Saido TC, et al: Calpain-dependent proteolysis of merlin occurs by oxidative stress in meningiomas: a novel hypothesis of tumorigenesis. Cancer 92:2662-2672, 2001
33. Kawate S, Fukusato T, Ohwada S, Watanuki A, Morishita Y: Amplification of c-myc in hepatocellular carcinoma: correlation with clinicopathologic features, proliferative activity and p53 overexpression. Oncology 57:157-163, 1999
34. Khoo MLC, Ezzat S, Freeman JL, Asa SL: Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 87:1810-1813, 2002
35. Koch A, Waha A, Tonn JC, Sörensen N, Berthold F, Wolter M, et al: Somatic mutations of WNT/wingless signaling pathway components in primitive neuroectodermal tumors. Int J Cancer 93:445-449, 2001
36. Kolligs FT, Kolligs B, Hajra KM, Hu G, Tani M, Cho KR, et al: γ-catenin is regulated by the APC tumor suppressor and its oncogenic activity is distinct from that of β-catenin. Genes Dev 14:1319-1331, 2000
37. Lastowska M, Cullinane C, Variend S, Cotterill S, Brown N, O'Neill S, et al: Comprehensive genetic and histopathologic study reveals three types of neuroblastoma tumors. J Clin Oncol 19:3080-3090, 2001
38. Lee SE, Johnson SP, Hale LP, Li J, Bullock N, Fuchs H, et al: Analysis of DNA mismatch repair proteins in human medulloblastoma. Clin Cancer Res 4:1415-1419, 1998
39. Leonard JR, Cai DX, Rivet DJ, Kaufman BA, Park TS, Levy BK, et al: Large cell/anaplastic medulloblastomas and medullomyoblastomas: clinicopathological and genetic features. J Neurosurg 95:82-88, 2001
40. Lillington DM, Goff LK, Kingston JE, Onadim Z, Price E, Domizio P, et al: High level amplification of N-MYC is not associated with adverse histology or outcome in primary retinoblastoma tumours. Br J Cancer 87:779-782, 2002
41. Michiels EM, Weiss MM, Hoovers JM, Baak JP, Voute PA, Baas F, et al: Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J Pediatr Hematol Oncol 24:205-210, 2002
42. Minamoto T, Ougolkov AV, Mai M: Detection of oncogenes in the diagnosis of cancers with active oncogenic signaling. Expert Rev Mol Diagn 2:565-575, 2002
43. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, Nakatsuru S, et al: Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1:229-233, 1992
44. Nawrocki B, Polette M, Van Hengel J, Tournier JM, Van Roy F, Birembaut P: Cytoplasmic redistribution of E-cadherin-catenin adhesion complex is associated with down-regulated tyrosine phosphorylation of E-cadherin in human bronchopulmonary carcinomas. Am J Pathol 153:1521-1530, 1998
45. Nicholson JC, Ross FM, Kohler JA, Ellison DW: Comparative genomic hybridization and histological variation in primitive neuroectodermal tumours. Br J Cancer 80:1322-1331, 1999
46. Nomura K: Special report of brain tumor registry of Japan (1969-1990). Neurol Med Chir 39:59-107, 1999
47. Packer RJ: Childhood medulloblastoma: progress and future challenges. Brain Dev 21:75-81, 1999
48. Packer RJ, Goldwein J, Nicholson HS, Vezina LG, Allen JC, Ris MD, et al: Treatment of children with medulloblastomas with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group Study. J Clin Oncol 17:2127-2136, 1999
49. Packer RJ, Sutton LN, D'Angio G, Evans AE, Schut L: Management of children with primitive neuroectodermal tumors of the posterior fossa/medulloblastoma. Pediatr Neurosci 12:272-282, 1985
50. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A: The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev 20:501-534, 1999
51. Reardon DA, Jenkins JJ, Sublett JE, Burger PC, Kun LE: Multiple genomic alterations including N-myc amplification in a primary large cell medulloblastoma. Pediatr Neurosurg 32:187-191, 2000
52. Ris MD, Packer R, Goldwein J, Jones-Wallace D, Boyett JM: Intellectual outcome after reduced-dose radiation therapy plus adjuvant chemotherapy for medulloblastoma: a Children's Cancer Group study. J Clin Oncol 19:3470-3476, 2001
53. Russo C, Pellarin M, Tingby O, Bollen AW, Lamborn KR, Mohapatra G, et al: Comparative genomic hybridization in patients with supratentorial and infratentorial primitive neuroectodermal tumors. Cancer 86:331-339, 1999
54. Simcha I, Geiger B, Yehuda-Levenberg S, Salomon D, Ben-Ze'ev A: Suppression of tumorigenicity by plakoglobin: an augmenting effect of N-cadherin. J Cell Biol 133:199-209, 1996
55. Siu IM, Lal A, Blankenship JR, Aldosari N, Riggins GJ: c-Myc promoter activation in medulloblastoma. Cancer Res 63:4773-4776, 2003
56. Syrigos KN, Harrington K, Waxman J, Krausz T, Pignatelli M: Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. J Urol 160:1889-1893, 1998
57. Visca P, Alo PL, Del Nonno F, Botti C, Trombetta G, Marandino F, et al: Immunohistochemical expression of fatty acid synthase, apoptotic-regulating genes, proliferating factors, and ras protein product in colorectal adenomas, carcinomas, and adjacent nonneoplastic mucosa. Clin Cancer Res 5:4111-4118, 1999
58. Watanabe T, Hirota Y, Arakawa Y, Fujisawa H, Tachibana O, Hasegawa M, et al: Frequent LOH at chromosome 12q22-23 and Apaf-1 inactivation in glioblastoma. Brain Pathol 13:431-439, 2003
59. Winn RA, Bremnes RM, Bemis L, Franklin WA, Miller YE, Cool C, et al: γ-Catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene 21:7497-7506, 2002
60. Yokota N, Nishizawa S, Ohta S, Date H, Sugimura H, Namba H, et al: Role of Wnt pathway in medulloblastoma oncogenesis. Int J Cancer 101:198-201, 2002
61. Zurawel RH, Chiappa SA, Allen C, Raffel C: Sporadic medulloblastomas contain oncogenic beta-catenin mutations. Cancer Res 58:896-899, 1998